Gulumbe Bashar H, Adesola Ridwan O
Department of Microbiology, Faculty of Science, Federal University, Birnin Kebbi, Kebbi State.
Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
Ann Med Surg (Lond). 2023 Feb 7;85(2):122-123. doi: 10.1097/MS9.0000000000000113. eCollection 2023 Feb.
One of the most significant risks to public health is ongoing antimicrobial resistance (AMR). Substandard and fraudulent medications, particularly in low- and middle-income countries (LMICs), are thought to have a role in the genesis and spread of AMR. There are numerous reports concerning the availability of subpar pharmaceuticals in developing countries, with no scientific evidence as to what exactly is included in some of the prescriptions supplied there. These counterfeit and inferior pharmaceuticals are a financial burden of up to US$200 billion, causing thousands of patient deaths, endangering both individual and public health,and undermining patient trust in the healthcare system. Poor quality and counterfeit antibiotics are often disregarded as possible causes of AMR in AMR studies. Therefore, we examined the issue of fake drugs in LMICs and its possible links to the emergence and spread of AMR.
对公众健康最大的风险之一是持续存在的抗菌药物耐药性（AMR）。劣质和假冒药品，尤其是在低收入和中等收入国家（LMICs），被认为在AMR的产生和传播中起到了作用。有许多关于发展中国家劣质药品供应情况的报告，但对于在那里提供的一些处方中究竟包含什么，没有科学证据。这些假冒和劣质药品造成了高达2000亿美元的经济负担，导致数千名患者死亡，危及个人和公众健康，并破坏患者对医疗系统的信任。在AMR研究中，质量差和假冒的抗生素通常被忽视，不被视为AMR的可能原因。因此，我们研究了低收入和中等收入国家假药问题及其与AMR出现和传播的可能联系。
